Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?

[1]  D. Kerr,et al.  Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Norman,et al.  Epirubicin, cisplatin, and protracted venous infusion of 5‐fluorouracil for esophagogastric adenocarcinoma: Response, toxicity, quality of life, and survival , 1996, Cancer.

[3]  I. Seymour,et al.  ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Padhani,et al.  Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF). , 1995, European journal of cancer.

[5]  T R Fleming,et al.  Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Hickish,et al.  Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  T. Hickish,et al.  Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Norman,et al.  Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. P. Pignon,et al.  Efficacy of adjuvant fluorouracil and folinic acid in colon cancer International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators , 1995, The Lancet.

[10]  H. Deeg,et al.  Impact of patient weight on non-relapse mortality after marrow transplantation. , 1995, Bone marrow transplantation.

[11]  R. Koretz,et al.  Nutrition support in patients with cancer: what do the data really show? , 1994, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[12]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[13]  A. Detsky,et al.  Parenteral nutrition in cancer patients undergoing chemotherapy: a meta-analysis. , 1990, Nutrition.

[14]  N. Kemeny,et al.  Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement , 1989, Cancer.

[15]  A. de Gramont,et al.  High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. , 1988, European journal of cancer & clinical oncology.

[16]  H. Rockette,et al.  Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. , 1988, Journal of the National Cancer Institute.

[17]  J. Simes,et al.  Total parenteral nutrition and cancer clinical trials , 1986, Cancer.

[18]  G. Sc,et al.  Nutritional support as an adjunct therapy of advanced cancer patients. , 1984 .

[19]  G. Bodey,et al.  Prognostic factors influencing survival of patients with advanced colorectal cancer: hepatic-artery infusion versus systemic intravenous chemotherapy for liver metastases. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Brennan.  Total parenteral nutrition in the cancer patient. , 1981, The New England journal of medicine.

[21]  Joseph R. Bertino,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.

[22]  T. Hickish,et al.  Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Gore,et al.  A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. , 1997, British Journal of Cancer.

[24]  D. Cunningham,et al.  Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation. , 1996, European journal of cancer.

[25]  S. Ellenberg,et al.  A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.